TNFSF10 and cancer: While the overall response of this study was reported to be poor (Clinical study report 20060340) despite the fact that the combination demonstrated a safety profile, the evaluation of TRAIL, or derivatives combined to HDACi or other epigenetic regulators, such as demethylating agents, is likely to represent an interesting therapeutic opportunity to treat patients suffering from cancer.